U.S. Cancer Contrast Media Market : Key Insights

1
Insights into the U.S. Cancer Contrast Media
Market Comprehensive Analysis and Forecast for
2024-2032
2

• Industry Insights

• U.S. Cancer Contrast Media Market size is poised
  to expand at 4.9 CAGR between 2024 and 2032
  driven by the continuous technological
  advancements in imaging and the launch of new
  products.
• Innovations in MRI and CT scanning technologies
  help improve image resolution and clarity while
  enhancing the effectiveness of contrast-enhanced
  studies. These advancements enable oncologists to
  detect and characterize cancerous lesions with
  greater precision. Additionally, the introduction
  of new and improved contrast media formulations
  is offering enhanced diagnostic capabilities and
  patient safety profiles. For instance, in April
  2023, GE HealthCare developed Pixxoscan, a
  macrocyclic gadolinium-based contrast agent
  (GBCA) for non-ionic MRI. Healthcare facilities
  are also striving to stay at the forefront of
  cancer diagnostics, boosting investments in
  latest imaging technologies and contrast agents,
  thereby accelerating the industry expansion.
• The U.S. cancer contrast media industry is
  segmented into product type, modality,
  application, and end-use.

3

• With respect to product type, the market size
  from the gadolinium-based contrast media segment
  is slated to depict 5.2 CAGR during 2024-2032.
  Gadolinium-based contrast agents play a pivotal
  role in enhancing the accuracy of cancer
  diagnostics through MRI imaging. With the surging
  prevalence of cancer in the U.S., the demand for
  advanced imaging techniques is increasing.
  Oncologists and radiologists highly prefer these
  contrast agents for better visualization of tumor
  characteristics and responses to therapies. With
  continuous advancements in imaging technology and
  the rising focus on early cancer detection, the
  demand for gadolinium-based contrast media is
  rising.
• Based on application, the U.S. cancer contrast
  media from the lung cancer segment is projected
  to record 4.9 growth rate between 2024 and 2032.
  This is attributed to the rising incidences of
  lung cancer and the demand for accurate
  diagnostic imaging. Additionally, the emphasis on
  early detection is driving research and
  development for more effective contrast agents.
  With the growing aging population and increased
  awareness, the segment is set to depict notable
  growth.

4

• Regional Analysis

In terms of end-use, the U.S. cancer contrast
media market from the diagnostic centers segment
generated substantial revenue in 2023 and is
estimated to grow at 5 CAGR from 2024-2032.
Diagnostics centers are essential hubs for cancer
screening, diagnosis, and monitoring as they
utilize advanced imaging techniques, such as MRI
and CT scans.

• Competitive Analysis

• Bayer AG
• Bracco Imaging S.p.A.
• GE Healthcare Technologies Inc
• Guerbet
• iMAX Diagnostic Imaging
• Lantheus Medical Imaging
• nanoPET Pharma GmbH
• Subtle Medical, Inc.
• Telix Pharmaceuticals Limited
• Trivitron Healthcare

5
Biotechnology Instruments Market _at_
https//www.gminsights.com/industry-analysis/us-ca
ncer-contrast-media-market
Request for sample of this research report _at_
https//www.gminsights.com/request-sample/detail/8
339
Request for customization _at_ https//www.gminsights
.com/roc/8339
6
Stay In Touch Social Media
7
THANK YOU
www.gminsights.com